Stroke Clinical Trials

Find Stroke Clinical Trials Near You

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial-2 (IRIS-2)

Status: Recruiting
Location: See all (22) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This study is a randomized, double-blind, placebo-controlled clinical trial. Investigators aim to assess the efficacy and safety of interleukin-6 receptor inhibitor combined with endovascular treatment in patients with acute anterior circulation large vessel occlusion stroke.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age 18 years or greater, male or female;

• Acute ischemic stroke caused by occlusion of intracranial segment of the internal carotid artery, middle cerebral artery M1 or proximal/dominant M2 segment;

• Decided to undergo emergency endovascular treatment;

• Time from stroke onset to arterial puncture within 24 hours;

• National Institutes of Health Stroke Scale (NIHSS) score ≥ 6;

• Signed informed consent from the patients or the legally authorized representatives.

Locations
Other Locations
China
The People's Hospital of Anyang
RECRUITING
Anyang
Xuanwu Hospital, Capital Medical University
RECRUITING
Beijing
Binzhou Medical University Hospital
RECRUITING
Binzhou
People's Hospital of Dongying
RECRUITING
Dongying
The First Affiliated Hospital of Harbin Medical University
RECRUITING
Harbin
Jun County People's Hospital
RECRUITING
Hebi
Linshu Country People's Hospital
RECRUITING
Linyi
Linyi People's Hospital
RECRUITING
Linyi
Qingdao Huangdao District Hospital of Traditional Chinese Medicine
RECRUITING
Qingdao
The second Hospital of Qinhuangdao
RECRUITING
Qinhuangdao
Lingshan County People's Hospital
RECRUITING
Qinzhou
Si Country People's Hospital
RECRUITING
Suzhou
Shanxi Medical University First Hospital
RECRUITING
Taiyuan
Yutian Hospital
RECRUITING
Tangshan
Tianyou Hospital Affliated to Wuhan University of Science &Technology
RECRUITING
Wuhan
Xiangyang No.1 People's hospital
RECRUITING
Xiangyang
The People's Hospital of Xianyang
RECRUITING
Xianyang
Xing'an league People's Hospital
RECRUITING
Xing’an
Daliuta Experimental District People's Hospital of Shenmu City
RECRUITING
Yulin
Henan Provincial People's Hospital
RECRUITING
Zhengzhou
Zhongxiang Traditional Chinese Medical Hospital
RECRUITING
Zhongxiang
Yiyuan Country People's Hospital
RECRUITING
Zibo
Contact Information
Primary
Xunming Ji, PhD/MD
jixm@ccmu.edu.cn
01083198962
Backup
Chuanjie Wu, MD
wuchuanjie@ccmu.edu.cn
01083199439
Time Frame
Start Date: 2025-12-05
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 692
Treatments
Experimental: Tocilizumab group
Endovascular treatment combined 240 mg tocilizumab injection once.
Placebo_comparator: Placebo group
Endovascular treatment combined equivalent volume of placebo once.
Related Therapeutic Areas
Sponsors
Leads: Capital Medical University

This content was sourced from clinicaltrials.gov